Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both
An Iron Balance Study Comparing Deferasirox, Deferoxamine and the Combination of Both Drugs
Sponsor: Weill Medical College of Cornell University
Listed as NCT00738413, this PHASE1/PHASE2 trial focuses on Thalassemia and remains ongoing. Sponsored by Weill Medical College of Cornell University, it has been updated 6 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE1_PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE1_PHASE2
First recorded
Aug 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Weill Medical College of Cornell University
For direct contact, visit the study record on ClinicalTrials.gov .